Freenome stock hits all-time high at 14.48 USD
- Investing.com
Metrics to compare | FRNM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFRNMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.6x | −46.6x | −0.3x | |
PEG Ratio | - | 2.07 | 0.00 | |
Price/Book | −1.1x | 2.6x | 2.6x | |
Price / LTM Sales | 43.6x | 12.5x | 3.0x | |
Upside (Analyst Target) | 18.3% | 8.9% | 54.6% | |
Fair Value Upside | Unlock | −32.7% | 8.6% | Unlock |
Freenome, Inc. operates as a biotechnology company in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops blood-based tests, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.